Global Gene Therapy On Cardiovascular Disease Market Strategic Research Report

Scope of the Report

The global Gene Therapy On Cardiovascular Disease market size is predicted to grow from US$ 603 million in 2025 to US$ 49,750 million in 2032; it is expected to grow at a CAGR of 88.9% from 2026 to 2032.

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%.

This report presents a comprehensive overview of the global Gene Therapy On Cardiovascular Disease market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Viral Gene Therapy
• Non-Viral Gene Therapy

Segment by players, this report covers

• Renovacor
• Gene Biotherapeutics
• AskBio
• Human Stem Cells Institute
• Novartis
• Biogen
• Gilead Sciences
• Sarepta Therapeutics
• Alnylam Pharmaceuticals
• Amgen
• Spark Therapeutics
• Akcea Therapeutics
• Sunway Biotech
• SIBIONO
• AnGes
• Orchard Therapeutics

Segment by Application

• Heart Disease
• Vascular Disease

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Gene Therapy On Cardiovascular Disease market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Heart Disease, Vascular Disease evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact